Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.33 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | AGL | P35573 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25381059 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| Hydrochloric Acid SCHEMBL143428 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| Hydrochloric Acid SCHEMBL201379 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| Hydrochloric Acid SCHEMBL201380 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| Hydrochloric Acid SCHEMBL29061369 | 1.00 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| SCHEMBL178593 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| SCHEMBL6026317 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| SCHEMBL201158 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| SCHEMBL201157 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL | |
| SCHEMBL203744 | 0.98 | SPHK1 (0.38) | SPHK1SLC1A2CHRNB2CHRNA4AGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057045-A | HCV NS3/4A protease inhibitor intermediate, and synthesis method and application thereof | 安徽红杉生物医药科技有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-122036924-A | Synthetic method of bionic collagen hexapeptide | 成都欣肽生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| WO-2024153106-A1 | OXADIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国药科大学 | 2024-07-25 | — | — | WO | disclosed |
| CN-115974807-B | 2-Phenyl-5-biphenyl-1, 3, 4-oxadiazole compound, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-117924139-A | Amplifying synthesis method of Fmoc-Hyp (tBu) -OH | 康化（上海）新药研发有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109957566-B | Modified oligonucleotides and compounds useful for synthesizing modified oligonucleotides | 广州市锐博生物科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-115974807-A | 2-phenyl-5-biphenyl-1,3,4-oxadiazole compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2023-04-18 | — | — | CN | disclosed |
| US-11485752-B2 | Modified oligonucleotides and compound that can be used for synthesizing same | GUANGZHOU RIBOBIO CO., LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
| CN-111718380-B | Carboline ruthenium complex and preparation method and application thereof | 首都医科大学 | 2022-05-06 | — | — | CN | disclosed |
| EP-0411664-B1 | 2-(2-Vinylpyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5374720-A | A thienamycins bactericides has nontoxic, side effect reduction against the kidney and central nervous system | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0435320-B1 | 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1994-10-05 | — | — | EP | disclosed |
| US-5112818-A | Antibiotics and bactericides | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| US-5095013-A | Antibiotics | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-03-10 | — | — | US | disclosed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | disclosed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
| EP-0435320-A1 | 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0411664-A2 | 2-(2-Vinylpyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-02-06 | — | — | EP | disclosed |
| EP-0281826-A2 | Process for the preparation of (R)-4-amino-3-hydroxy-butyric acid | Degussa Aktiengesellschaft (DE) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485752-B2 | Modified oligonucleotides and compound that can be used for synthesizing same | ADAR, POLRMT, DCLRE1B | CHRNB4 4012/4885CHRNA3 4386/4885CHRNA7 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.